EGFR and non-small cell lung carcinoma: First-generation EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, and second-generation TKIs including afatinib and dacomitinib have consistently demonstrated high efficacy in treating metastatic non-small cell lung cancer with specific EGFR mutations, particularly exon 19 deletions and the L858R mutation [1, 2].